Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches (NCT07432347) | Clinical Trial Compass
RecruitingNot Applicable
Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches
Italy270 participantsStarted 2026-01-01
Plain-language summary
This is a national, observational, retrospective, cross-sectional, non-profit study focused on patients with HCC. The study aims to characterize the expression and function of novel noncoding regulatory transcripts, including those containing TEsin the microenvironment of liver tumors, with emphasis on their role in T cell dysfunction.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
1. Histological/radiological (LR-4 o 5)diagnosis of hepatocellular carcinoma (HCC).
2. Solid tumor fresh tissue availability from HCC biospy or surgical resectionas per standard clinical practice, and/orHCC FFPE archival samples availability.
3. Capability of understanding and signing an inform consent form.
4. Known hepatits B and C status, including HBeAg (positive or negative), viral load (HBVDNA e HCV-RNA), HCV genotype, whether sustained virological response (SVR)was obtainedand potential antiviral treatments received (including direct antiretroviral therapy(DAA)and interferon). These parameters will be exploited to stratify patients and analyze the impact of the virological status on microenvironmental immunological features, with particular regards to immunesuppression mechanisms.
What they're measuring
1
Characterize the molecular mechanisms underlying T cell dysfunction